Dr Reddy's Laboratories rose 0.85% to Rs 3,867.95 after the company announced the launch of desmopressin acetate injection USP, 4 mcg/mL in the US market.
The drug major on 6 May 2020 announced announced the launch of desmopressin acetate injection USP, 4 mcg/mL single-dose ampules, a therapeutic equivalent generic version of DDAVP injection , 4 mcg/mL, approved by the US Food and Drug Administration (USFDA).Desmopressin acetate is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation.
The DDAVP brand and generic market had US sales of approximately $20.9 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health.
Dr. Reddy's Desmopressin Acetate injection USP, 4 mcg/mL is available in a carton of ten 1 mL single-dose ampules.
On 9 April 2020, Dr Reddy's Laboratories had said that its API (Active Pharmaceutical Ingredient) manufacturing plant 5 at Miryalaguda, Nalgonda district in Telangana received the Establishment Inspection Report (EIR) from the US-based drug regulator, USFDA, indicating closure of the audit. The inspection classification of this facility is determined as voluntary action indicated (VAI).
On a consolidated basis, Dr Reddy's Laboratories reported a net loss of Rs 538.40 crore in Q3 December 2019 compared with a net profit of Rs 500.30 crore in Q3 December 2018. Net sales rose 13.86% to Rs 4,383.80 crore in Q3 December 2019 over Q3 December 2018.
Dr Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)